Stockscreener 앱 받기
4.15
7.16%
-0.32
시간 외 거래:
4.11
-0.04
-0.96%
전일 마감가:
$4.47
열려 있는:
$4.02
하루 거래량:
278.75K
Relative Volume:
0.70
시가총액:
$40.63M
수익:
$21.73M
순이익/손실:
$-91.17M
주가수익비율:
-5.6081
EPS:
-0.74
순현금흐름:
$-286.43M
1주 성능:
-14.43%
1개월 성능:
+10.67%
6개월 성능:
-56.93%
1년 성능:
-79.05%
1일 변동 폭
$4.02
$4.232
1주일 범위
$4.02
$5.15
52주 변동 폭
$3.56
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
명칭
Bluebird Bio Inc
전화
339-499-9300
주소
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
BLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.15 | 40.63M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-11-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-11-15 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-08-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-12-11 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2023-12-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-19 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-28 | 개시 | JP Morgan | Overweight |
| 2023-03-07 | 개시 | Robert W. Baird | Outperform |
| 2022-08-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-07 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-11-08 | 재확인 | Barclays | Equal Weight |
| 2021-11-08 | 재확인 | Canaccord Genuity | Hold |
| 2021-11-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-11-08 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | 재확인 | Wedbush | Neutral |
| 2021-11-08 | 재확인 | Wells Fargo | Equal Weight |
| 2021-08-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | 재개 | William Blair | Mkt Perform |
| 2021-08-09 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-03-10 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-02-17 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-02-16 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-11-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | 개시 | Mizuho | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-27 | 업그레이드 | Stifel | Hold → Buy |
| 2020-02-19 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | 재개 | BofA/Merrill | Buy |
| 2020-02-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-10-01 | 개시 | Stifel | Hold |
| 2019-08-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | 업그레이드 | Maxim Group | Hold → Buy |
모두보기
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
Bluebird says Ayrmid missed deadline for rival takeover bid - BioPharma Dive
bluebird bio's board opts for sale to U.S. investment firms - The Business Journals
Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid - MarketScreener
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer - BioSpace
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird - Endpoints News
bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertaint - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - BioSpace
Bluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock Fell - Nasdaq
Bluebird bio shares fall amid acquisition woes - Investing.com Australia
Tesla, Cal-Maine Foods, Bluebird Bio - TradingView
Bluebird Bio falls after Ayrmid fails to give binding offer - TradingView
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9% - MSN
bluebird bio confirms that Ayrmid, Ltd. has not delivered a bind - GuruFocus
Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement - MarketScreener
bluebird bio backs Carlyle and SK Capital takeover bid - Investing.com
Gene Therapy Market Insights 2025Trends, Growth Forecast & - openPR.com
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
Sickle Cell Disease Treatment Market to Hit $7.04 Billion By 2032 - openPR.com
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
Biotechnology Company Grants Commercial License for Cell Manufacturing Platform Use to Advance SCD Therapy - Docwire News
Companies team up to support sickle cell gene therapy Lyfgenia - Sickle Cell Disease News
bluebird bio, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Gene Therapy Market Demand, Growth and Future Scope 2025-2032 | - openPR.com
Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking - Benzinga
Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener
Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire
BlueBird Shares Are Up Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq
bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com
Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView
Bluebird bio receives non-binding bid for up to $110.5 million - MSN
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha
bluebird bio confirms rival takeover bid - The Pharma Letter
Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Bluebird Bio: A $110.5 Million Bid and the Future of Gene Therapy - AInvest
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus
New suitor emerges for struggling bluebird bio - FirstWord Pharma
Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid - GuruFocus.com
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer - Fierce Pharma
bluebird bio (BLUE) Receives Higher Bid from Ayrmid Pharma - GuruFocus
bluebird bio sees higher offer for company from Ayrmid Pharma - Seeking Alpha
Bluebird Bio (BLUE) Receives Higher Buyout Bid from Ayrmid - GuruFocus
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
bluebird bio receives higher acquisition offer from Ayrmid - Investing.com India
Bluebird Bio shares rally 11% in late trade on buyout offer - TradingView
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Bluebird Bio Inc (BLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
1.22%
자본화:
|
볼륨(24시간):